Effectiveness of the BPaL(M) Regimen for Drug-Resistant Tuberculosis in Ukraine under Programmatic Conditions

Abstract Bedaquiline, pretomanid, and linezolid, with or without moxifloxacin, have revolutionized treatment for drug-resistant tuberculosis. In Ukraine, we observed an 86% (n=394/460) success rate under programmatic conditions when drugs were accessible, exceeding prior estimates (58%) and aligning with trials (80–90%). However, access and implementation remain a concern in conflict-affected settings.